Parrot L, Dong C, Carbonnel F, et al. - Among patients suffering from Crohn disease (CD) refractory to anti-tumor necrosis factor (TNF), similar effectiveness of ustekinumab and vedolizumab in induction was evident in this study, however, maintenance with ustekinumab seemed to be more effective than with vedolizumab.

• This is a systematic review and meta-analysis of five studies (four were retrospective and one was prospective) that compared ustekinumab and vedolizumab in patients with CD refractory to anti-TNF (of 1026 patients, 659 treated with ustekinumab and 367 received vedolizumab).

• At week 14, there were similar outcomes in terms of clinical remission (odds ratios OR, 1.36), steroid-free clinical remission (OR 1.24) and biological remission (OR 0.80) rates between the two treatments.

• At week 52, higher rates of clinical remission (OR 1.87), steroid-free clinical remission (OR 1.56), biological remission (OR 1.86) and treatment persistence (OR 2.37) were achieved with ustekinumab.